ADVERSE REACTIONS SECTION.

ADVERSE REACTIONS. Occasional temporary stinging, burning and conjunctival redness may occur with the use of proparacaine. rare, severe, immediate-type, apparently hyperallergic corneal reaction characterized by acute, intense and diffuse epithelial keratitis, gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and, sometimes, iritis with descemetitis has been reported.Allergic contact dermatitis from proparacaine with drying and fissuring of the fingertips has also been reported.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females.

CLINICAL PHARMACOLOGY SECTION.

CLINICAL PHARMACOLOGY. Proparacaine hydrochloride ophthalmic solution is rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes.

CONTRAINDICATIONS SECTION.

CONTRAINDICATIONS. Proparacaine hydrochloride ophthalmic solution should be considered contraindicated in patients with known hypersensitivity to any of the ingredients of this preparation.

DESCRIPTION SECTION.

DESCRIPTION. Proparacaine hydrochloride ophthalmic solution 0.5% is topical local anesthetic for ophthalmic use. The active ingredient is represented by the structural formula:Established name: Proparacaine HydrochlorideChemical name: Benzoic acid, 3-amino-4-propoxy-,2-(diethylamino) ethyl ester, monohydrochloride.Molecular Weight: 330.85Each mL contains: Active: proparacaine hydrochloride 5mg 0.5%. Preservative: benzalkonium chloride (0.01%). Inactives: glycerin; and purified water. The pH may be adjusted with hydrochloric acid and/or sodium hydroxide. chemical.

DOSAGE & ADMINISTRATION SECTION.

DOSAGE AND ADMINISTRATION. Usual Dosage: Removal of foreign bodies and sutures, and for tonometry: to drops (in single instillations) in each eye before operating. Short corneal and conjunctival procedures: drop in each eye every to 10 minutes for to doses.NOTE: Proparacaine hydrochloride ophthalmic solution should be clear to straw-color. If the solution becomes darker, discard the solution.

GERIATRIC USE SECTION.

Geriatric Use. No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.

HOW SUPPLIED SECTION.

HOW SUPPLIED. Proparacaine hydrochloride ophthalmic solution 0.5% is supplied in 15 mL DROP-TAINER dispensers.NDC: 70518-3408-00PACKAGING: in CARTON, 15 mL in BOTTLE TYPE 0Storage: Bottle must be stored in unit carton to protect contents from light. Store bottles under refrigeration at - 8C (36 46F).Rx OnlyRepackaged and Distributed By:Remedy Repack, Inc.625 Kolter Dr. Suite Indiana, PA 1-724-465-8762.

INDICATIONS & USAGE SECTION.

INDICATIONS AND USAGE. Proparacaine hydrochloride ophthalmic solution is indicated for procedures in which topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g. tonometry, gonioscopy, removal of corneal foreign bodies, and for short corneal and conjunctival procedures.

NURSING MOTHERS SECTION.

Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to nursing woman.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

DRUG: Proparacaine HydrochlorideGENERIC: Proparacaine HydrochlorideDOSAGE: SOLUTION/ DROPSADMINSTRATION: OPHTHALMICNDC: 70518-3408-0PACKAGING: 15 mL in BOTTLEOUTER PACKAGING: in CARTONACTIVE INGREDIENT(S):PROPARACAINE HYDROCHLORIDE 5mg in 1mLINACTIVE INGREDIENT(S):BENZALKONIUM CHLORIDEGLYCERINWATERHYDROCHLORIC ACIDSODIUM HYDROXIDE. PROPARACAINE HYDROCHLORIDE 5mg in 1mL. BENZALKONIUM CHLORIDE. GLYCERIN. WATER. HYDROCHLORIC ACID. SODIUM HYDROXIDE. RemedyLabel.

PEDIATRIC USE SECTION.

Pediatric Use. Safety and effectiveness of proparacaine hydrochloride ophthalmic solution in pediatric patients have been established. Use of proparacaine hydrochloride is supported by evidence from adequate and well-controlled studies in adults and children over the age of twelve, and safety information in neonates and other pediatric patients.

PRECAUTIONS SECTION.

PRECAUTIONS. Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females.. Pregnancy. Pregnancy Category C: Animal reproduction studies have not been conducted with proparacaine hydrochloride ophthalmic solution 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to pregnant woman only if clearly needed.. Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to nursing woman.. Pediatric Use. Safety and effectiveness of proparacaine hydrochloride ophthalmic solution in pediatric patients have been established. Use of proparacaine hydrochloride is supported by evidence from adequate and well-controlled studies in adults and children over the age of twelve, and safety information in neonates and other pediatric patients.. Geriatric Use. No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.

PREGNANCY SECTION.

Pregnancy. Pregnancy Category C: Animal reproduction studies have not been conducted with proparacaine hydrochloride ophthalmic solution 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to pregnant woman only if clearly needed.

SPL UNCLASSIFIED SECTION.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.DROP-TAINER is registered trademark of Alcon Research, Ltd.Rev. June 2012Repackaged and Distributed By:Remedy Repack, Inc.625 Kolter Dr. Suite Indiana, PA 1-724-465-8762.

WARNINGS SECTION.

WARNINGS. NOT FOR INJECTION FOR TOPICAL OPHTHALMIC USE ONLY. Prolonged use of topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.